Longeveron Inc. (LGVN) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Miami, FL, 미국. 현재 CEO는 Stephen H. Willard.
LGVN 을(를) 보유 IPO 날짜 2021-02-12, 25 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $26.1M.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
